chronic lymphocytic leukemia

Overview

Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm characterized by the accumulation of small, typically CD5-positive B lymphocytes in blood, bone marrow, and lymphoid tissues. It is closely related to small lymphocytic lymphoma (SLL), and the two are generally considered different clinical presentations of the same disease spectrum. CLL is biologically notable for its dependence on B-cell receptor signaling, anti-apoptotic pathways such as BCL-2, and interactions with the tumor microenvironment, all of which have made it a major focus of targeted therapy development.

In contemporary hematology, CLL is a prototypic disease for precision medicine. Bruton tyrosine kinase inhibitors, BCL-2 inhibitors such as venetoclax, and combination regimens have reshaped treatment, especially for relapsed/refractory disease. Ongoing research continues to address resistance mechanisms, treatment duration, safety, and outcomes in patients with comorbidities or prior exposure to targeted agents.

Focus of Latest Publications

Recent publications have continued to position CLL as a key target for next-generation targeted therapy studies, particularly in relapsed/refractory disease and in the setting of resistance to Bruton tyrosine kinase inhibitor therapy.

A phase 1/2 study evaluated duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL and Richter transformation. This work reflects the ongoing strategy of combining pathway-directed agents, here pairing a PI3K-pathway inhibitor with the BCL-2 inhibitor venetoclax, to improve activity in difficult-to-treat disease. The study specifically used a regimen of 25 mg twice daily duvelisib plus 400 mg daily venetoclax.

Another recent report presented final phase 2 results of acalabrutinib in both treatment-naive and relapsed/refractory CLL. acalabrutinib is a selective, covalent Bruton tyrosine kinase inhibitor approved for CLL/SLL, and the study reinforces its role as a standard targeted therapy in this disease. Related real-world work also examined acalabrutinib monotherapy as first-line treatment, supporting the broader clinical use of BTK inhibition in CLL.

Several publications focused on the expanding BTK inhibitor landscape and resistance biology. A review of novel BTK inhibitors and degraders highlighted that covalent and non-covalent BTK inhibitors have extended benefit in relapsed/refractory and BTK inhibitor-resistant CLL/SLL, but that unmet need remains for highly refractory disease. This is consistent with the broader therapeutic shift away from chemoimmunotherapy toward continuous or fixed-duration targeted regimens.

Mechanistic and translational studies also addressed resistance to BTK inhibition. One study reported that IL-16 was transcriptionally upregulated, actively secreted, and sufficient to induce ibrutinib resistance across multiple CD9-positive models, including CLL. This suggests that cytokine-mediated signaling may contribute to treatment failure in BTK inhibitor-treated disease. Another study used single-cell RNA sequencing in patients with CLL treated with ibrutinib and found distinct tumor and immunosuppressive T-cell phenotypes, underscoring the importance of the tumor microenvironment during BTK inhibitor therapy.

Additional work examined emerging BTK-directed agents under clinical investigation, including nemtabrutinib, and highlighted the broader development of novel inhibitors and degraders such as BGB-16673, docirbrutinib, birletinib, and bexobrutideg. These studies reflect the effort to overcome resistance mutations and improve durability of response in CLL.

Resistance-associated BTK mutations were also part of the recent research context. The extracted methods included BTK C481S, L528W, and A428D, which are relevant to BTK inhibitor resistance biology. Computational studies using molecular dynamics simulations, MM-PBSA analysis, and related approaches were used to understand mutation-induced binding changes in BTK with non-covalent inhibitors, supporting the rationale for next-generation agents in CLL.

Beyond direct antitumor therapy, recent work also examined clinical and health-system aspects of CLL care. An economic evaluation assessed the cost-effectiveness of BTK inhibitors in South Africa, and another study investigated how hypertension, a common comorbidity in CLL, affects survival and treatment. These studies emphasize that CLL management is shaped not only by drug efficacy but also by toxicity, comorbidity burden, and access to therapy.

Key Publications

• Jun Interpretable multi-omics integration across mixed-order tensors with MANTRA. (Molecular systems biology, 2026, PMID 42315933): "On a Chronic Lymphocytic Leukemia (CLL) dataset, the joint analysis of a third-order drug-response tensor and a second-order RNA-seq matrix with MANTRA revealed clinically relevant patient subgroups that were missed by single-view or matrix-based analyses."
• Jun Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial. (Blood, 2026, PMID 41911073): "Fixed-duration venetoclax combinations have become a standard first-line treatment in chronic lymphocytic leukemia (CLL)."
• Jun A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation. (Blood advances, 2026, PMID 41886642): "In this phase 1/2 study we evaluated duvelisib plus venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Richter transformation (RT)."
• Jun Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. (Blood advances, 2026, PMID 41915892): "Acalabrutinib is a selective, covalent Bruton tyrosine kinase inhibitor approved for marketing in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)."
• Jun Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting. (Journal of hematology & oncology, 2026, PMID 42252468): "Although covalent and non-covalent Bruton tyrosine kinase inhibitors (BTKi) have extended clinical benefit to relapsed/refractory (R/R) and BTKi-resistant chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), there remains an unmet need for additional B-cell receptor (BCR) pathway targeted therapies for highly refractory disease."
• Jun Computational insights into mutation-induced binding changes in Bruton's Tyrosine Kinase with non-covalent inhibitors. (Journal of biomolecular structure & dynamics, 2026, PMID 40372209): "Bruton's Tyrosine Kinase (BTK) inhibitors have proven effective in treating B-cell malignancies like Chronic Lymphocytic Leukemia (CLL)."
• May IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas. (Blood, 2026, PMID 42213644): "IL-16 was transcriptionally upregulated, actively secreted, and sufficient to induce ibrutinib resistance across multiple CD9-positive models of MZL, mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and activated B-cell-like diffuse large B-cell lymphoma."
• May Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study. (Blood cancer discovery, 2026, PMID 41678768): "We explored the efficacy of the combination of ibrutinib + venetoclax in patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL)."
• May Acquired Pseudo-Pelger-Huet anomaly in a patient with chronic lymphocytic leukemia treated with acalabrutinib. (Journal of hematopathology, 2026, PMID 42103972): "...a patient with chronic lymphocytic leukemia (CLL) who was admitted to hospital because of a crural ulceration."
• May Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies. (CPT: pharmacometrics & systems pharmacology, 2026, PMID 42067967): "Nemtabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor under clinical investigation in patients with hematologic malignancies, including chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)."